Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 19/20 | 0.58 |
| ▸ | PIM3 | Q86V86 | 11/20 | 0.58 |
| ▸ | PIM1 | P11309 | 9/20 | 0.58 |
| ▸ | PRKCA | P17252 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11924097 | 1.00 | PIM2 (0.58) | PIM2PIM3PIM1PRKCAGSK3B | |
| SCHEMBL11924095 | 0.92 | PIM2 (0.48) | PIM2PIM3PIM1PRKCAGSK3B | |
| SCHEMBL11924094 | 0.92 | PIM2 (0.48) | PIM2PIM3PIM1PRKCAGSK3B | |
| SCHEMBL11923884 | 0.88 | PIM2 (0.57) | PIM2PIM3PIM1 | |
| SCHEMBL11923888 | 0.88 | PIM2 (0.57) | PIM2PIM3PIM1 | |
| SCHEMBL11924182 | 0.87 | PIM2 (0.56) | PIM2PIM3PIM1PRKCAGSK3B | |
| SCHEMBL11924176 | 0.87 | PIM2 (0.56) | PIM2PIM3PIM1PRKCAGSK3B | |
| SCHEMBL11924022 | 0.86 | PIM2 (0.56) | PIM2PIM3PIM1PRKCAGSK3B | |
| SCHEMBL11924024 | 0.86 | PIM2 (0.56) | PIM2PIM3PIM1PRKCAGSK3B | |
| SCHEMBL11924096 | 0.83 | CHEK1 (0.65) | PIM2PIM3PIM1PRKCAGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669259-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669259-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20120208826-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208826-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| WO-2011025706-A2 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208826-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | CDK1, MTOR, GAK | PIM2 829/4885PIM3 951/4885PIM1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.